Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B

R. YANG,* Y . ZHAO, † X. WANG,‡ J . SUN,§ J . J IN , ¶ D. WU,** R . CHARNIGO,† † A. O ’BRIEN,†† Z. ZHONG‡‡ and P . RENDO†† *Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin; †Peking Union Medical College Hospital, Beijing; ‡Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai; §Nanfang Hospital, Southern Medical University, Guangzhou; ¶The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou; **The First Affiliated Hospital of Soochow University, Suzhou, China; ††Pfizer Inc, Collegeville, PA USA; and ‡‡Pfizer Inc, Beijing, China